Cutaneous Squamous Cell Carcinoma

  • Nina R. Blank
  • Kishwer Nehal
  • Erica LeeEmail author


Cutaneous squamous cell carcinoma (cSCC) may be treated surgically, with destructive modalities, or through the use of topical agents. The risk of cSCC metastasis has been shown to increase with tumor size and depth, ear location, and immunosuppression. For cSCC lesions with higher-risk features, excision with postoperative margin assessment and Mohs micrographic surgery (MMS) are considered most effective, with MMS best utilized in locations with minimal excess tissue and/or near vital anatomic structures. While cryosurgery and electrodesiccation and curettage may be used for low-risk cSCC, current evidence supports the use of photodynamic therapy and topical agents for low-risk cSCC in situ only.


Nonmelanoma skin cancer Squamous cell carcinoma Cutaneous squamous cell carcinoma Surgical excision Mohs micrographic surgery Electrodesiccation and curettage Cryotherapy Photodynamic therapy Imiquimod 5-Fluorouracil 


  1. 1.
    Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30(5 Pt 1):774–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294(6):681–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Kaldor J, Shugg D, Young B, Dwyer T, Wang YG. Non-melanoma skin cancer: ten years of cancer-registry-based surveillance. Int J Cancer. 1993;53(6):886–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 1997;133(6):735–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988–98. Br J Dermatol. 2000;143(6):1224–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Brewster DH, Bhatti LA, Inglis JH, Nairn ER, Doherty VR. Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992–2003. Br J Dermatol. 2007;156(6):1295–300.CrossRefPubMedGoogle Scholar
  8. 8.
    Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–66.CrossRefPubMedGoogle Scholar
  9. 9.
    Hussein MR. Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol. 2005;32(3):191–205.CrossRefPubMedGoogle Scholar
  10. 10.
    English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer. 1998;76(5):628–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol. 2011;164(2):291–307.CrossRefPubMedGoogle Scholar
  12. 12.
    Alfonso JH, Martinsen JI, Pukkala E, et al. Occupation and relative risk of cutaneous squamous cell carcinoma (cSCC): A 45-year follow-up study in 4 Nordic countries. J Am Acad Dermatol. 2016;75(3):548–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169(3):502–18.CrossRefPubMedGoogle Scholar
  14. 14.
    Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169(2):250–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Squamous Cell Skin Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) 2016; Version 1. 2017: Accessed 20 Oct 2016.
  16. 16.
    Rogers HW, Coldiron BM. Analysis of skin cancer treatment and costs in the United States Medicare population, 1996–2008. Dermatol Surg. 2013;39(1 Pt 1):35–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41(11):1214–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4(8):462–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Dana Bolotin MA. Electrosurgery. In: Robinson JK, CWH DMS, Fratila A, editors. Surgery of the skin: procedural dermatology. 3rd ed. London/New York/Oxford/Philadelphia/St. Louis/Sydney/Toronto: Saunders Elsevier; 2015.Google Scholar
  20. 20.
    Samarasinghe V, Madan V. Nonmelanoma skin cancer. J Cutan Aesthet Surg. 2012;5(1):3–10.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pasquali P. Cryosurgery. In: Robinson JK, CWH DMS, Fratila A, editors. Surgery of the skin: procedural dermatology. 3rd ed. London/New York/Oxford/Philadelphia/St. Louis/Sydney/Toronto: Saunders Elsevier; 2015.Google Scholar
  22. 22.
    Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen’s disease. Cochrane Database Syst Rev. 2013;(6):Cd007281.Google Scholar
  24. 24.
    Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Rowe DE, Carroll RJ, Day CL. Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ (Clinical research ed). 2013;347:f6153.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Knox JM, Freeman RG, Duncan WC, Heaton CL. Treatment of skin cancer. South Med J. 1967;60(3):241–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Honeycutt WM, Jansen GT. Treatment of squamous cell carcinoma of the skin. Arch Dermatol. 1973;108(5):670–2.CrossRefPubMedGoogle Scholar
  29. 29.
    Reschly MJ, Shenefelt PD. Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas. J Drugs Dermatology: JDD. 2010;9(7):773–6.Google Scholar
  30. 30.
    Shiffman NJ. Squamous cell carcinomas of the skin of the pinna. Can J Surg. 1975;18(3):279–83.PubMedGoogle Scholar
  31. 31.
    Williamson GS, Jackson R. Treatment of squamous cell carcinoma of the skin by electrodesiccation and curettage. Can Med Assoc J. 1964;90:408–13.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Tromovitch TA. Skin cancer; treatment by curettage and desiccation. Calif Med. 1965;103:107–8.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Thestrup-Pedersen K, Ravnborg L, Morbus Bowen RF. A description of the disease in 617 patients. Acta Derm Venereol. 1988;68(3):236–9.PubMedGoogle Scholar
  34. 34.
    Stevens DM, Kopf AW, Gladstein A, Bart RS. Treatment of Bowen’s disease with grenz rays. Int J Dermatol. 1977;16(5):329–39.CrossRefPubMedGoogle Scholar
  35. 35.
    Kuflik EG. Cryosurgery for skin cancer: 30-year experience and cure rates. Dermatol Surg. 2004;30(2 Pt 2):297–300.PubMedGoogle Scholar
  36. 36.
    Lindemalm-Lundstam B, Dalenback J. Prospective follow-up after curettage-cryosurgery for scalp and face skin cancers. Br J Dermatol. 2009;161(3):568–76.CrossRefPubMedGoogle Scholar
  37. 37.
    Graham GF, Clark LC. Statistical analysis in cryosurgery of skin cancer. Clin Dermatol. 1990;8(1):101–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Olson JM, Alam M, Asgari MM. Needs assessment for general dermatologic surgery. Dermatol Clin. 2012;30(1):153–66. xCrossRefPubMedGoogle Scholar
  39. 39.
    Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg. 2011;37(10):1394–411.CrossRefPubMedGoogle Scholar
  40. 40.
    Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol. 1988;119(2):231–40.CrossRefPubMedGoogle Scholar
  41. 41.
    Cox NH, Dyson P. Wound healing on the lower leg after radiotherapy or cryotherapy of Bowen’s disease and other malignant skin lesions. Br J Dermatol. 1995;133(1):60–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen’s disease. Dermatol Clin. 2007;25(1):81–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B. 1995;29(1):53–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Lui H, Salasche S, Kollias N, et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. Arch Dermatol. 1995;131(6):737–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Pennington DG, Waner M, Knox A. Photodynamic therapy for multiple skin cancers. Plast Reconstr Surg. 1988;82(6):1067–71.CrossRefPubMedGoogle Scholar
  46. 46.
    Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br J Dermatol. 2008;159(1):137–44.CrossRefPubMedGoogle Scholar
  47. 47.
    Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed. 2003;19(3):134–41.CrossRefPubMedGoogle Scholar
  48. 48.
    Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol. 2001;137(3):319–24.PubMedGoogle Scholar
  49. 49.
    Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S. Imiquimod 5% cream in the treatment of Bowen’s disease and invasive squamous cell carcinoma. J Am Acad Dermatol. 2006;55(2):324–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025–32.CrossRefPubMedGoogle Scholar
  51. 51.
    Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol. 2001;44(3):462–70.CrossRefPubMedGoogle Scholar
  52. 52.
    Rosen T, Harting M, Gibson M. Treatment of Bowen’s disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg. 2007;33(4):427–31; discussion 431–422.PubMedGoogle Scholar
  53. 53.
    Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-Fluorouracil. J Cutan Med Surg. 2003;7(2):101–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol. 2006;142(6):729–35.CrossRefPubMedGoogle Scholar
  55. 55.
    Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol. 2003;148(3):539–43.CrossRefPubMedGoogle Scholar
  56. 56.
    Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Tan PY, Ek E, Su S, Giorlando F, Dieu T. Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study. Plast Reconstr Surg. 2007;120(4):910–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Nemet AY, Deckel Y, Martin PA, et al. Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol. 2006;142(2):293–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Griffiths RW, Feeley K, Suvarna SK. Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. Br J Plast Surg. 2002;55(4):287–92.CrossRefPubMedGoogle Scholar
  60. 60.
    Thomas SS, Matthews RN. Squamous cell carcinoma of the pinna: a 6-year study. Br J Plast Surg. 1994;47(2):81–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Hansen JP, Drake AL, Walling HW. Bowen’s Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg. 2008;34(7):878–83.PubMedGoogle Scholar
  62. 62.
    Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–20.CrossRefPubMedGoogle Scholar
  63. 63.
    Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. experience over 10 years. J Am Acad Dermatol. 2005;53(2):253–60.CrossRefPubMedGoogle Scholar
  64. 64.
    Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg. 2010;36(10):1544–53.CrossRefPubMedGoogle Scholar
  65. 65.
    Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133(5):1188–96.CrossRefPubMedGoogle Scholar
  66. 66.
    van der Eerden PA, Prins ME, Lohuis PJ, Balm FA, Vuyk HD. Eighteen years of experience in Mohs micrographic surgery and conventional excision for nonmelanoma skin cancer treated by a single facial plastic surgeon and pathologist. Laryngoscope. 2010;120(12):2378–84.CrossRefPubMedGoogle Scholar
  67. 67.
    Mullen JT, Feng L, Xing Y, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006;13(7):902–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Moore BA, Weber RS, Prieto V, et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005;115(9):1561–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Califano JA, Lydiatt WM, Nehal KS, O’Sullivan B, Schmults C, Seethala RR, Weber RS, Shah Jatin P. Cutaneous squamous cell carcinoma of the head and neck. 8th ed. New York: Springer; 2017.Google Scholar
  70. 70.
    Lee EH. Patient expectations and performance measures in dermatologic surgery. Clin Dermatol. 2016;34(1):111–3.CrossRefPubMedGoogle Scholar
  71. 71.
    Ahmed I, Berth-Jones J, Charles-Holmes S, O’Callaghan CJ, Ilchyshyn A. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease: a prospective study. Br J Dermatol. 2000;143(4):759–66.CrossRefPubMedGoogle Scholar
  72. 72.
    Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br J Dermatol. 1996;135(5):766–71.CrossRefPubMedGoogle Scholar
  73. 73.
    Lee EH, Klassen AF, Lawson JL, Cano SJ, Scott AM, Pusic AL. Patient experiences and outcomes following facial skin cancer surgery: a qualitative study. Australas J Dermatol. 2016;57(3):e100–4.CrossRefPubMedGoogle Scholar
  74. 74.
    Asgari MM, Bertenthal D, Sen S, Sahay A, Chren MM. Patient satisfaction after treatment of nonmelanoma skin cancer. Dermatol Surg. 2009;35(7):1041–9.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    El-Gamal HM, Dufresne RG, Saddler K. Electrosurgery, pacemakers and ICDs: a survey of precautions and complications experienced by cutaneous surgeons. Dermatol Surg. 2001;27(4):385–90.PubMedGoogle Scholar
  76. 76.
    Wolfe CM, Hatfield K, Cognetta AB Jr. Cellulitis as a postprocedural complication of topical 5-aminolevulinic acid photodynamic therapy in the treatment of actinic keratosis. J Drugs Derm. 2007;6(5):544–8.Google Scholar
  77. 77.
    Desai T, Chen CL, Desai A, Kirby W. Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon. Dermatol Surg. 2012;38(1):97–103.CrossRefPubMedGoogle Scholar
  78. 78.
    Alam M, Ibrahim O, Nodzenski M, et al. Adverse events associated with mohs micrographic surgery: multicenter prospective cohort study of 20,821 cases at 23 centers. JAMA Derm. 2013;149(12):1378–85.CrossRefGoogle Scholar
  79. 79.
    Cook JL, Perone JB. A prospective evaluation of the incidence of complications associated with Mohs micrographic surgery. Arch Dermatol. 2003;139(2):143–52.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Maragh SL, Brown MD. Prospective evaluation of surgical site infection rate among patients with Mohs micrographic surgery without the use of prophylactic antibiotics. J Am Acad Dermatol. 2008;59(2):275–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Rogers HD, Desciak EB, Marcus RP, Wang S, MacKay-Wiggan J, Eliezri YD. Prospective study of wound infections in Mohs micrographic surgery using clean surgical technique in the absence of prophylactic antibiotics. J Am Acad Dermatol. 2010;63(5):842–51.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136(12):1524–30.CrossRefPubMedGoogle Scholar
  83. 83.
    Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst. 2008;100(17):1215–22.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of DermatologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations